Change in the Antimicrobial Resistance Profile of Extended-Spectrum β-Lactamase-Producing
Antimicrobial resistance profile
Escherichia coli
Extended-spectrum β-lactamase
Fluoroquinolone resistance
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
12
07
2019
accepted:
23
07
2019
entrez:
17
9
2019
pubmed:
17
9
2019
medline:
17
9
2019
Statut:
ppublish
Résumé
This study aimed to investigate the trends and antimicrobial resistance profile of extended-spectrum β-lactamase-producing A total of 1,303 The proportion of ESBL-EC among all the Our findings indicate a changing antimicrobial resistance profile of ESBL-EC, particularly to fluoroquinolones. Determination of the prevalence and antimicrobial resistance of ESBL-EC will help physicians in selecting the initial empirical treatment for patients with ESBL-EC infections.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to investigate the trends and antimicrobial resistance profile of extended-spectrum β-lactamase-producing
METHODS
METHODS
A total of 1,303
RESULTS
RESULTS
The proportion of ESBL-EC among all the
CONCLUSIONS
CONCLUSIONS
Our findings indicate a changing antimicrobial resistance profile of ESBL-EC, particularly to fluoroquinolones. Determination of the prevalence and antimicrobial resistance of ESBL-EC will help physicians in selecting the initial empirical treatment for patients with ESBL-EC infections.
Identifiants
pubmed: 31523337
doi: 10.14740/jocmr3928
pmc: PMC6731046
doi:
Types de publication
Journal Article
Langues
eng
Pagination
635-641Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
J Antimicrob Chemother. 2009 Jan;63(1):72-9
pubmed: 19004839
J Clin Microbiol. 2009 Nov;47(11):3780-2
pubmed: 19741070
Clin Infect Dis. 2010 Aug 1;51(3):286-94
pubmed: 20572763
Clin Microbiol Infect. 2013 Feb;19(2):161-8
pubmed: 22332968
Diagn Microbiol Infect Dis. 2012 Oct;74(2):201-3
pubmed: 22796185
J Med Microbiol. 2013 Jul;62(Pt 7):1038-43
pubmed: 23538565
PLoS One. 2013 May 15;8(5):e64359
pubmed: 23691204
Clin Microbiol Rev. 2013 Oct;26(4):744-58
pubmed: 24092853
Clin Microbiol Rev. 2014 Jul;27(3):543-74
pubmed: 24982321
Clin Infect Dis. 2015 May 1;60(9):1319-25
pubmed: 25586681
Antimicrob Agents Chemother. 2015 Sep;59(9):5107-13
pubmed: 26100708
Jpn J Antibiot. 2015 Apr;68(2):75-84
pubmed: 26182812
J Hosp Infect. 2016 Jan;92(1):33-41
pubmed: 26597637
Travel Med Infect Dis. 2016 Nov - Dec;14(6):561-567
pubmed: 27769900
J Infect Chemother. 2017 Jun;23(6):339-348
pubmed: 28391954
Intern Med. 2017;56(14):1807-1815
pubmed: 28717075
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923864
J Infect Chemother. 2018 May;24(5):330-340
pubmed: 29555391
J Infect Chemother. 2018 Nov;24(11):944-947
pubmed: 29803763
PLoS One. 2018 Aug 29;13(8):e0202276
pubmed: 30157275